-
Merrill Lynch economist David Rosenberg is betting on the curve.
FORBES: Curveball
-
In a Sept. 23 note to investors, Merrill Lynch analyst David W. Munno, who covers antibiotic maker Cubist , a Vicuron competitor, wrote that he suspected Pfizer had received an approvable letter.
FORBES: Pfizer Plays A Guessing Game
-
"Now that oil prices and mortgage rates have stopped falling, we will be back lamenting the downturn in the housing market and its spreading effects on the economy in the second quarter, " Merrill Lynch economist David Rosenberg wrote.
CNN: Spring into home-selling action